Advertisement
Australia markets closed

  • ALL ORDS

    8,082.30
    -67.80 (-0.83%)
     

  • ASX 200

    7,814.40
    -66.90 (-0.85%)
     

  • AUD/USD

    0.6695
    +0.0015 (+0.22%)
     

  • OIL

    80.00
    +0.77 (+0.97%)
     

  • GOLD

    2,419.80
    +34.30 (+1.44%)
     

  • Bitcoin AUD

    99,709.93
    +2,231.73 (+2.29%)
     

  • CMC Crypto 200

    1,366.54
    -7.31 (-0.53%)
     

  • AUD/EUR

    0.6155
    +0.0016 (+0.26%)
     

  • AUD/NZD

    1.0905
    -0.0001 (-0.01%)
     

  • NZX 50

    11,699.79
    -28.27 (-0.24%)
     

  • NASDAQ

    18,546.23
    -11.73 (-0.06%)
     

  • FTSE

    8,420.26
    -18.39 (-0.22%)
     

  • Dow Jones

    40,003.59
    +134.21 (+0.34%)
     

  • DAX

    18,704.42
    -34.39 (-0.18%)
     

  • Hang Seng

    19,553.61
    +177.08 (+0.91%)
     

  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

Dynavax to Present at TD Cowen's 44th Annual Health Care Conference

PR Newswire
·1-min read

EMERYVILLE, Calif., Feb. 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at TD Cowen's 44th Annual Health Care Conference on Monday, March 4 at 10:30 a.m. ET.

(PRNewsfoto/Dynavax Technologies)
(PRNewsfoto/Dynavax Technologies)

The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations.

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn and Twitter.

ADVERTISEMENT

For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499

Nicole Arndt
narndt@dynavax.com
510-665-7264

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-td-cowens-44th-annual-health-care-conference-302073426.html

SOURCE Dynavax Technologies